Encore AMC Partners Served as Exclusive Financial Advisor to TechData Service Company
Encore AMC Partners today announced the completion of the sale of TechData Service Company, LLC (“TechData”) to Graham Partners (“Graham”). The transaction closed on July 1, 2026.
Graham Partners, a private investment firm targeting advanced manufacturing and technology-enabled services businesses, formed Quantive Intelligence (“QI”) through the acquisitions of TechData, LLX Solutions, LLC (“LLX”), and R Square Technology, Inc. (“R Square”) (together, the “Legacy Entities”). Collectively, the founder-led Legacy Entities have over 40 years of operating history serving 14 of the top 20 large pharma sponsors by R&D spend and leading biotech organizations. Together, these Legacy Entities form a global organization of over 700 employees defined by an exemplary focus on improving patient lives through scientific inquiry and execution.
We are honored to have served as TechData’s exclusive financial advisor on this transaction.”
— Othon Herrera, Managing Partner of Encore AMC Partners
Headquartered in King of Prussia, Pennsylvania, with additional presence in Massachusetts, Greater China, and a newly formed operation in India, QI is being formed to create a purpose-built decision sciences platform that transforms complex clinical data into confident, regulatory-ready decisions. The Legacy Entities each provide specialized expertise in biostatistics and statistical programming that pharmaceutical and biotechnology organizations rely on to accelerate regulatory approvals and bring new therapies to market. The platform brings together premier organizations that are highly reputable in their respective areas of expertise, backed by experienced founders with decades-long reputations for excellence and quality in the CRO space.
Read More: SalesTechStar Interview with Sahil Rekhi, Chief Revenue Officer at Graia
Graham believes the decision sciences niche presents near-term opportunities for disruptive innovation, as regulatory expectations, increased data volumes, and real-time clinical trials have created a demand for validation frameworks that do not exist today. QI marks the continuation of Graham’s 15+ years of experience investing in medical devices and life sciences, where past and current portfolio companies work in regulated environments, building end-to-end processes across the value chain to bring medical products and / or drugs to market, and innovating to increase productivity and efficiency. Graham has actively pursued an investment in pharma services, specifically submission-stage clinical development services, and believes that QI is well aligned within its broader life sciences thesis.
Read More: Beyond CRM: How SalesTech is Shaping the Future of Deal Management?
“QI brings together founder-built businesses with deeply loyal customers and exceptional talent that share a common focus on delivering critical biometrics expertise. We’re excited to leverage our life sciences experience and bench of resources as we aim to build QI into a leading provider in the space,” said Josh Wilson, Managing Partner and Chief Operating Officer at Graham Partners.
“We are honored to have served as TechData’s exclusive financial advisor on this transaction,” said Othon Herrera, Managing Partner of Encore AMC Partners. “Navigating a deal of this scale in the specialized CRO sector and securing a partner in Graham Partners who understands both the industry and the business reflects the kind of outcome we work to deliver for every client.”
